Drugs / VILANTEROL .ALPHA.-PHENYL CINNAMATE
VILANTEROL .ALPHA.-PHENYL CINNAMATE
also known as
GW642444H
Small molecule targets ADRB2 via activation
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00381667 | Aug 2006 → Jan 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VILANTEROL .ALPHA.-PHENYL CINNAMATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084173 ↗ |
| Known as | GW642444H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00381667 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL1084173 ↗ |
| Modality | Small molecule | — CHEMBL1084173 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL1084173 ↗ |